Michael Warner, MD
MOHS-Micrographic Surgery · Frederick, MDNPI 1942282371
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,676 of the $30,625 with a category attached, or 93.6%. AbbVie accounts for 96.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $7,872 and has fallen 52.3% since, to $3,754 in 2025. Among mohs-micrographic surgery clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $195.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Galderma Laboratories, L.p.$614
- Regeneron Healthcare Solutions, Inc.$175
- Sanofi$66
- Almirall LLC$59
- E.r. Squibb & Sons, L.L.C.$37
- plus $94 from 6 others
What the payments were for
- Speaking & faculty fees$28,67694%
- Food & beverage$1,9496%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $29,581 |
| Galderma Laboratories, L.p. | 32 | $614 |
| Regeneron Healthcare Solutions, Inc. | 8 | $175 |
| Sanofi | 2 | $66 |
| Almirall LLC | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Arcutis Biotherapeutics, Inc. | 1 | $24 |
| DUSA Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| VYNE Pharmaceuticals Inc. | 1 | $14 |
| Biowound Solutions, Inc. | 1 | $10 |
| Biofrontera Inc. | 1 | $9 |
How this compares
$30,625 in reported general payments places this provider in the 95th percentile of 26 mohs-micrographic surgery providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 27 | $1,611 |
| Imiquimod | 32 | $1,088 |
| Metronidazole | 17 | $467 |
| Ketoconazole | 49 | $437 |
| Triamcinolone Acetonide | 15 | $98 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Frederick
- David MezebishFrederick$33
- Cylburn SodenLaurel$201K
- Trinh PhamTowson$10K
- Julia Santoso-PhamTowson$10K
- Hyland CroninChevy Chase$5K
- Zaineb MakhzoumiBaltimore$5K
- Zain SyedLutherville$4K
- Stephanie ClementsMillersville$4K
- Jennifer CooperAbingdon$3K
- Faith EstersonBaltimore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.